Article Text

Download PDFPDF
Initial presentation of lymphangioleiomyomatosis in third trimester of pregnancy
  1. Lily Alkemade1,
  2. Meike A T Berghuis1,
  3. Bart Koopman2 and
  4. Mariëlle G van Pampus1
  1. 1Obstetrics and Gynaecology, OLVG, Amsterdam, The Netherlands
  2. 2Pulmonary Medicine, OLVG, Amsterdam, The Netherlands
  1. Correspondence to Ms Lily Alkemade; lilyalkemade93{at}hotmail.com

Abstract

Lymphangioleiomyomatosis (LAM) is a progressive cystic lung disease which mostly affects premenopausal women and could be exacerbated by pregnancy. Therefore, it is thought that oestrogen plays an important role in LAM pathogenesis. Here, a case of LAM is described in which the first presentation of symptoms occurred during the third trimester of pregnancy. Symptoms included acute onset dyspnoea and chest pain at gestational age of 39 weeks and 2 days. A CT was performed which showed multiple thin-walled cysts and a small pneumothorax. Serum levels of vascular endothelial growth factor-D (VEGF-D) was 1200 pg/mL. The typical cystic lung changes on chest CT in combination with elevated VEGF-D is diagnostic for LAM. Given the risk of respiratory complications, the decision was made to deliver the baby at a gestational age of 39 weeks and 6 days by a planned caesarean section. Both mother and child were discharged home in good condition.

  • obstetrics
  • gynaecology and fertility
  • respiratory system
  • pregnancy
  • pneumothorax

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors LA wrote the article. BK provided the information about lung diseases as he is a pulmonologist. MATB and MGvP provided information about the obstetric part.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.